Edificio Pleyades-Vitalys
Murcia, 30100, Spain
NCT Number: NCT06392893
The purpose of this research is to test the hypothesis that the consumption of meat products without additives, in comparison with their analogues with additives, could be beneficial in terms of modifying health markers. A 5-week clinical trial with two parallel arms will be performed with two parallel arms. Changes in different serum biomarkers of lipid metabolism, glucose, oxidative stress and inflammation will be analysed. Biomarkers related to digestive health, such as short chain fatty acid (SCFA) production and impact on the gut microbiota, will also be evaluated. Finally, factors such as body mass index (BMI), body fat percentage and markers of exposure to additives will be measured.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Murcia, 30100, Spain
One of the most discussed reasons for reducing meat consumption is its additive content. Additives are compounds added to food products to preserve their technological properties, to avoid contamination by microorganisms, regulate acidity, and even act as thickeners, emulsifiers, and stabilisers. However, there is some controversy over the actual health effects of additives in meat products, as their long-term effect has not been studied for many of them. On the other hand, not all additives have the same effect, as for antioxidants such as sodium citrate (E-331) and sodium erythorbate (E-316), as well as acidity regulators such and triphosphates (E-451) no side effects or significant toxicity have been reported on healthy individuals. However, other additives such as carrageenans (E-407) have been associated with intestinal inflammation and inflammatory bowel diseases by several animal studies. Negative effects have also been found for sodium nitrite (E-250), which can lead to the formation of carcinogenic N-nitrosamines.
Due to the rising concern about additives in meat products, it is of particular interest to identify the possible health effects of a processed meat product without additives and allergens. Therefore, the hypothesis of this study is that the production of additive-free meat products may be of interest to the consumers and may have a beneficial effect on their health.
To confirm this hypothesis, two meat products without additives or allergens were produced (cooked ham and cooked turkey breast), and a double-blind, randomised, controlled, unicentric trial with two parallel arms will be conducted.
Prior to the start of the intervention period (baseline time) anthropometric measurements and blood, faeces and urine samples will be taken. 58 participants will take alternately 100g of cooked ham or cooked turkey breast (control or reformulated depending on the group) 6 days a week for 5 weeks, noting the rest of their diet in a collection notebook that they will then give to the researchers. After the intervention (final time), anthropometric measurements and blood, faeces and urine samples will be taken again.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.
Consumption of meat products without additives and allergens (6 days a week; 5 weeks).
Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.
Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.
Consumption of commercial meat products (6 days a week; 5 weeks).
Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Seric measurement of triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol.
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Seric measurement of malondialdehyde (MDA), serum glutathione peroxidase (GPx), catalase (CAT), oxidized LDL, Ferric reducing ability of plasma (FRAP) and ABTS (2,2'-azino-bis(3-methylbenzothiazole-6-sulfonic acid).
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Seric measurement of C-reactive protein (CRP), Tumor necrosis factor α (TNF-α), Interleukin 1β (IL-1β), Interleukin 6 (IL-6) and Interleukin 10 (IL-10).
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Measurement of changes in the abundance of the different bacteria present in the gut.
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Measurement of FRAP levels in faeces.
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Measurement of FRAP levels in urine.
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Measurement of acetate, propionate, butyrate and total SCFA in faeces.
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Time frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Universidad de Murcia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06993740
Anesthesia, Cardiovascular Diseases
Jakarta, DKI Jakarta, Indonesia
View Trial DetailsNCT07726979
Athletic Performance, Bone Metabolism
Surabaya, Jawa Timur - East Java, Indonesia
View Trial DetailsNCT05385055
Behavior, Inflammation
Kyustendil, Bulgaria
View Trial DetailsNCT06122038
Inflammation, Muscle Damage
Saint Charles, Missouri, United States
View Trial Details